154 related articles for article (PubMed ID: 24366975)
1. Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies.
Bozzi F; Manenti G; Conca E; Stacchiotti S; Messina A; Dagrada G; Gronchi A; Panizza P; Pierotti MA; Tamborini E; Pilotti S
Neuro Oncol; 2014 Jan; 16(1):72-80. PubMed ID: 24366975
[TBL] [Abstract][Full Text] [Related]
2. Phase II study on lapatinib in advanced EGFR-positive chordoma.
Stacchiotti S; Tamborini E; Lo Vullo S; Bozzi F; Messina A; Morosi C; Casale A; Crippa F; Conca E; Negri T; Palassini E; Marrari A; Palmerini E; Mariani L; Gronchi A; Pilotti S; Casali PG
Ann Oncol; 2013 Jul; 24(7):1931-1936. PubMed ID: 23559153
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review.
Launay SG; Chetaille B; Medina F; Perrot D; Nazarian S; Guiramand J; Moureau-Zabotto L; Bertucci F
BMC Cancer; 2011 Oct; 11():423. PubMed ID: 21970335
[TBL] [Abstract][Full Text] [Related]
4. Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury.
Magnaghi P; Salom B; Cozzi L; Amboldi N; Ballinari D; Tamborini E; Gasparri F; Montagnoli A; Raddrizzani L; Somaschini A; Bosotti R; Orrenius C; Bozzi F; Pilotti S; Galvani A; Sommer J; Stacchiotti S; Isacchi A
Mol Cancer Ther; 2018 Mar; 17(3):603-613. PubMed ID: 29237806
[TBL] [Abstract][Full Text] [Related]
5. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.
Shalaby A; Presneau N; Ye H; Halai D; Berisha F; Idowu B; Leithner A; Liegl B; Briggs TR; Bacsi K; Kindblom LG; Athanasou N; Amary MF; Hogendoorn PC; Tirabosco R; Flanagan AM
J Pathol; 2011 Feb; 223(3):336-46. PubMed ID: 21171079
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib inhibits growth of a patient-derived chordoma xenograft.
Siu IM; Ruzevick J; Zhao Q; Connis N; Jiao Y; Bettegowda C; Xia X; Burger PC; Hann CL; Gallia GL
PLoS One; 2013; 8(11):e78895. PubMed ID: 24260133
[TBL] [Abstract][Full Text] [Related]
7. A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-κB signaling in chordoma biology.
Trucco MM; Awad O; Wilky BA; Goldstein SD; Huang R; Walker RL; Shah P; Katuri V; Gul N; Zhu YJ; McCarthy EF; Paz-Priel I; Meltzer PS; Austin CP; Xia M; Loeb DM
PLoS One; 2013; 8(11):e79950. PubMed ID: 24223206
[TBL] [Abstract][Full Text] [Related]
8. EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.
Scheipl S; Barnard M; Cottone L; Jorgensen M; Drewry DH; Zuercher WJ; Turlais F; Ye H; Leite AP; Smith JA; Leithner A; Möller P; Brüderlein S; Guppy N; Amary F; Tirabosco R; Strauss SJ; Pillay N; Flanagan AM
J Pathol; 2016 Jul; 239(3):320-34. PubMed ID: 27102572
[TBL] [Abstract][Full Text] [Related]
9. MTNR1B loss promotes chordoma recurrence by abrogating melatonin-mediated β-catenin signaling repression.
Liu L; Wang T; Yang X; Xu C; Liao Z; Wang X; Su D; Li Y; Zhou H; Qiu X; Chen Y; Huang D; Lian C; Su P
J Pineal Res; 2019 Sep; 67(2):e12588. PubMed ID: 31140197
[TBL] [Abstract][Full Text] [Related]
10. C-reactive protein as a prognostic factor in patients with chordoma of lumbar spine and sacrum--a single center pilot study.
Hobusch GM; Bodner F; Walzer S; Marculescu R; Funovics PT; Sulzbacher I; Windhager R; Panotopoulos J
World J Surg Oncol; 2016 Apr; 14():111. PubMed ID: 27091202
[TBL] [Abstract][Full Text] [Related]
11. Molecular targeted therapies in advanced or metastatic chordoma patients: facts and hypotheses.
Lebellec L; Aubert S; Zaïri F; Ryckewaert T; Chauffert B; Penel N
Crit Rev Oncol Hematol; 2015 Jul; 95(1):125-31. PubMed ID: 25682222
[TBL] [Abstract][Full Text] [Related]
12. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.
Gril B; Palmieri D; Bronder JL; Herring JM; Vega-Valle E; Feigenbaum L; Liewehr DJ; Steinberg SM; Merino MJ; Rubin SD; Steeg PS
J Natl Cancer Inst; 2008 Aug; 100(15):1092-103. PubMed ID: 18664652
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma.
Akhavan-Sigari R; Abili M; Gaab MR; Rohde V; Zafar N; Emami P; Ostertag H
Neurosurg Rev; 2015 Jan; 38(1):89-98; discussion 98-9. PubMed ID: 25323095
[TBL] [Abstract][Full Text] [Related]
14. Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.
Scaltriti M; Chandarlapaty S; Prudkin L; Aura C; Jimenez J; Angelini PD; Sánchez G; Guzman M; Parra JL; Ellis C; Gagnon R; Koehler M; Gomez H; Geyer C; Cameron D; Arribas J; Rosen N; Baselga J
Clin Cancer Res; 2010 May; 16(9):2688-95. PubMed ID: 20406840
[TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of a primary human chordoma xenograft model.
Siu IM; Salmasi V; Orr BA; Zhao Q; Binder ZA; Tran C; Ishii M; Riggins GJ; Hann CL; Gallia GL
J Neurosurg; 2012 Apr; 116(4):801-9. PubMed ID: 22283186
[TBL] [Abstract][Full Text] [Related]
16. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.
Singh A; Lun X; Jayanthan A; Obaid H; Ruan Y; Strother D; Chi SN; Smith A; Forsyth P; Narendran A
Mol Oncol; 2013 Jun; 7(3):497-512. PubMed ID: 23375777
[TBL] [Abstract][Full Text] [Related]
17. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
[TBL] [Abstract][Full Text] [Related]
18. Medical treatment of advanced chordomas.
Colia V; Stacchiotti S
Eur J Cancer; 2017 Sep; 83():220-228. PubMed ID: 28750274
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterization of chordoma xenografts generated from a novel primary chordoma cell source and two chordoma cell lines.
Karikari IO; Gilchrist CL; Jing L; Alcorta DA; Chen J; Richardson WJ; Gabr MA; Bell RD; Kelley MJ; Bagley CA; Setton LA
J Neurosurg Spine; 2014 Sep; 21(3):386-93. PubMed ID: 24905390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
